A Feasibility Study of Alendronate as Treatment for Osteonecrosis in Adults With Sickle Cell Disease
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Age 18-80 years with SCD (any genotype, confirmed by hemoglobin electrophoresis or high performance liquid chromatography)
• Ability to provide written informed consent
• Ability to lay on a dual-energy X-ray absorptiometry (DXA) scanner
• Negative urine pregnancy test for anyone of childbearing potential at study entry
Locations
United States
California
UC Davis Comprehensive Cancer Center
RECRUITING
Sacramento
Contact Information
Primary
Leyla Y Teos, PhD
lyteos@ucdavis.edu
(916) 460-2749
Time Frame
Start Date: 2026-03-09
Estimated Completion Date: 2027-12-31
Participants
Target number of participants: 30
Treatments
Experimental: Alendronate group
Single-arm prospective cohort of 30 adult with SCD
Related Therapeutic Areas
Sponsors
Collaborators: Doris Duke Charitable Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Leads: University of California, Davis